Tech Company Financing Transactions
Convergen Funding Round
Qiming Ventures and private investors participated in a $10 million Seed capital raise for Convergen. The round closed on 12/8/2025.
Transaction Overview
Company Name
Announced On
12/8/2025
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Seed
Investors
Qiming Ventures (Lead Investor)
Proceeds Purpose
The company intends to use the funds to accelerate the development of its proprietary TrimTAC platform and advance its early pipeline of therapies for neurodegenerative disorders and diseases with massive unmet medical needs.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Suzhou, Undisclosed
China
Suzhou, Undisclosed
China
Phone
Undisclosed
Email Address
Not Recorded
Overview
Convergen is a biotech company pioneering TrimTAC--next-generation bifunctional degraders that leverage TRIM21 to selectively clear pathological multimeric proteins. Founded to address unmet medical needs in neurodegenerative disease and beyond, the company combines cutting-edge academic research with industry-proven drug development expertise to advance therapies for significantly unmet medical needs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Co-Founder
Ting Han
Co-Founder
Jinquan Sun
Browse more venture capital transactions:
Prev: 12/8/2025: Tuhk venture capital transaction
Next: 12/8/2025: Corma venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to document all VC transactions involving tech companies. All VC database entries reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs